SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ionis Pharmaceuticals Inc. – ‘10-K’ for 12/31/21 – ‘EX-4.11’

On:  Thursday, 2/24/22, at 5:38pm ET   ·   As of:  2/25/22   ·   For:  12/31/21   ·   Accession #:  874015-22-79   ·   File #:  0-19125

Previous ‘10-K’:  ‘10-K’ on 2/24/21 for 12/31/20   ·   Next:  ‘10-K’ on 2/22/23 for 12/31/22   ·   Latest:  ‘10-K’ on 2/21/24 for 12/31/23   ·   54 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/25/22  Ionis Pharmaceuticals Inc.        10-K       12/31/21  106:22M

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Ionis Pharmaceuticals, Inc. 10-K 12-31-2021         HTML   2.36M 
 2: EX-4.11     Instrument Defining the Rights of Security Holders  HTML     47K 
                -- exhibit4-11                                                   
 3: EX-10.19    Material Contract -- exhibit10-19                   HTML     89K 
 4: EX-10.60    Material Contract -- exhibit10-60                   HTML     65K 
 5: EX-10.83    Material Contract -- exhibit10-83                   HTML     48K 
 6: EX-10.84    Material Contract -- exhibit10-84                   HTML    830K 
 7: EX-21.1     Subsidiaries List -- exhibit21-1                    HTML     30K 
 8: EX-23.1     Consent of Expert or Counsel -- exhibit23-1         HTML     30K 
 9: EX-31.1     Certification -- §302 - SOA'02 -- exhibit31-1       HTML     36K 
10: EX-31.2     Certification -- §302 - SOA'02 -- exhibit31-2       HTML     36K 
11: EX-32       Certification -- §906 - SOA'02 -- exhibit32-1       HTML     32K 
17: R1          Document and Entity Information                     HTML     97K 
18: R2          Consolidated Balance Sheets                         HTML    138K 
19: R3          Consolidated Balance Sheets (Parenthetical)         HTML     48K 
20: R4          Consolidated Statements of Operations               HTML    129K 
21: R5          Consolidated Statements of Comprehensive Income     HTML     62K 
                (Loss)                                                           
22: R6          Consolidated Statements of Stockholders' Equity     HTML    110K 
23: R7          Consolidated Statements of Cash Flows               HTML    168K 
24: R8          Consolidated Statements of Cash Flows               HTML     41K 
                (Parenthetical)                                                  
25: R9          Organization and Significant Accounting Policies    HTML    357K 
26: R10         Investments                                         HTML    156K 
27: R11         Long-Term Obligations and Commitments               HTML    109K 
28: R12         Stockholders' Equity                                HTML    130K 
29: R13         Income Taxes                                        HTML    176K 
30: R14         Collaborative Arrangements and Licensing            HTML    163K 
                Agreements                                                       
31: R15         Akcea Merger                                        HTML     49K 
32: R16         Severance and Retention Costs related to our        HTML     58K 
                Restructured Operations                                          
33: R17         Employment Benefits                                 HTML     35K 
34: R18         Legal Proceedings                                   HTML     35K 
35: R19         Fourth Quarter Financial Data (Unaudited)           HTML     82K 
36: R20         Organization and Significant Accounting Policies    HTML    415K 
                (Policies)                                                       
37: R21         Organization and Significant Accounting Policies    HTML    267K 
                (Tables)                                                         
38: R22         Investments (Tables)                                HTML    158K 
39: R23         Long-Term Obligations and Commitments (Tables)      HTML    101K 
40: R24         Stockholders' Equity (Tables)                       HTML    105K 
41: R25         Income Taxes (Tables)                               HTML    175K 
42: R26         Collaborative Arrangements and Licensing            HTML     94K 
                Agreements (Tables)                                              
43: R27         Akcea Merger (Tables)                               HTML     44K 
44: R28         Severance and Retention Costs related to our        HTML     57K 
                Restructured Operations (Tables)                                 
45: R29         Fourth Quarter Financial Data (Unaudited) (Tables)  HTML     82K 
46: R30         Organization and Significant Accounting Policies,   HTML     35K 
                Basis of Presentation (Details)                                  
47: R31         Organization and Significant Accounting Policies,   HTML     78K 
                Basic Net Income (Loss) per Share (Details)                      
48: R32         Organization and Significant Accounting Policies,   HTML    105K 
                Diluted Net Income (Loss) per Share (Details)                    
49: R33         Organization and Significant Accounting Policies,   HTML    113K 
                Revenue Recognition (Details)                                    
50: R34         Organization and Significant Accounting Policies,   HTML     42K 
                Contracts Receivable (Details)                                   
51: R35         Organization and Significant Accounting Policies,   HTML     32K 
                Deferred Revenue (Details)                                       
52: R36         Organization and Significant Accounting Policies,   HTML     59K 
                Research, Development and Patent Expenses                        
                (Details)                                                        
53: R37         Organization and Significant Accounting Policies,   HTML     40K 
                Accrued Liabilities (Details)                                    
54: R38         Organization and Significant Accounting Policies,   HTML     37K 
                Noncontrolling Interest in Akcea Therapeutics,                   
                Inc. (Details)                                                   
55: R39         Organization and Significant Accounting Policies,   HTML     45K 
                Cash, Cash Equivalents and Investments (Details)                 
56: R40         Organization and Significant Accounting Policies,   HTML     44K 
                Inventory Valuation (Details)                                    
57: R41         Organization and Significant Accounting Policies,   HTML     67K 
                Property, Plant and Equipment (Details)                          
58: R42         Organization and Significant Accounting Policies,   HTML     32K 
                Long-Lived Assets (Details)                                      
59: R43         Organization and Significant Accounting Policies,   HTML     65K 
                Stock-Based Compensation Expense (Details)                       
60: R44         Organization and Significant Accounting Policies,   HTML     66K 
                Accumulated Other Comprehensive Loss (Details)                   
61: R45         Organization and Significant Accounting Policies,   HTML    205K 
                Convertible Debt (Details)                                       
62: R46         Organization and Significant Accounting Policies,   HTML     36K 
                Call Spread (Details)                                            
63: R47         Organization and Significant Accounting Policies,   HTML     32K 
                Segment Information (Details)                                    
64: R48         Organization and Significant Accounting Policies,   HTML    127K 
                Fair Value Measurements (Details)                                
65: R49         Investments, Contract Maturity of                   HTML     50K 
                Available-for-Sale Securities (Details)                          
66: R50         Investments, Summary of Investments (Details)       HTML    108K 
67: R51         Investments, Investments Temporarily Impaired       HTML     52K 
                (Details)                                                        
68: R52         Long-Term Obligations and Commitments, Long-Term    HTML     56K 
                Obligations (Details)                                            
69: R53         Long-Term Obligations and Commitments, Convertible  HTML    101K 
                Debt and Call Spread (Details)                                   
70: R54         Long-Term Obligations and Commitments, Research     HTML     48K 
                and Development and Manufacturing Facilities                     
                (Details)                                                        
71: R55         Long-Term Obligations and Commitments, Maturity     HTML     58K 
                Schedules for Annual Debt and Other Obligations                  
                (Details)                                                        
72: R56         Long-Term Obligations and Commitments, Operating    HTML     86K 
                Leases (Details)                                                 
73: R57         Long-Term Obligations and Commitments, Future       HTML     53K 
                Payments for Operating Lease Liabilities (Details)               
74: R58         Stockholders' Equity, Preferred and Common Stock    HTML     59K 
                (Details)                                                        
75: R59         Stockholders' Equity, Share Repurchase Program      HTML     37K 
                (Details)                                                        
76: R60         Stockholders' Equity, Stock Plans (Details)         HTML    134K 
77: R61         Stockholders' Equity, Stock Option Activity         HTML     86K 
                (Details)                                                        
78: R62         Stockholders' Equity, Restricted Stock Unit         HTML     62K 
                Activity (Details)                                               
79: R63         Stockholders' Equity, Stock-based Compensation      HTML     47K 
                Expense (Details)                                                
80: R64         Stockholders' Equity, Stock-based Valuation         HTML     48K 
                Information (Details)                                            
81: R65         Income Taxes, Income (Loss) Before Income Taxes     HTML     40K 
                (Details)                                                        
82: R66         Income Taxes, Income Tax Expense (Benefit)          HTML     55K 
                (Details)                                                        
83: R67         Income Taxes, Reconciliation of Statutory to        HTML    116K 
                Effective Tax Rate (Details)                                     
84: R68         Income Taxes, Deferred Tax Assets and Liabilities   HTML     64K 
                (Details)                                                        
85: R69         Income Taxes, Tax Credit Carryforwards (Details)    HTML     41K 
86: R70         Income Taxes, Gross Unrecognized Tax Benefits       HTML     44K 
                (Details)                                                        
87: R71         Collaborative Arrangements and Licensing            HTML    206K 
                Agreements, Biogen (Details)                                     
88: R72         Collaborative Arrangements and Licensing            HTML    121K 
                Agreements, AstraZeneca (Details)                                
89: R73         Collaborative Arrangements and Licensing            HTML     90K 
                Agreements, Bayer (Details)                                      
90: R74         Collaborative Arrangements and Licensing            HTML     69K 
                Agreements, GSK (Details)                                        
91: R75         Collaborative Arrangements and Licensing            HTML     99K 
                Agreements, Novartis (Details)                                   
92: R76         Collaborative Arrangements and Licensing            HTML     96K 
                Agreements, Roche (Details)                                      
93: R77         Collaborative Arrangements and Licensing            HTML     33K 
                Agreements, PTC Therapeutics (Details)                           
94: R78         Collaborative Arrangements and Licensing            HTML     43K 
                Agreements, Bicycle License Agreement (Details)                  
95: R79         Collaborative Arrangements and Licensing            HTML     52K 
                Agreements, Alnylam Pharmaceuticals, Inc.                        
                (Details)                                                        
96: R80         Akcea Merger (Details)                              HTML     74K 
97: R81         Severance and Retention Costs related to our        HTML     49K 
                Restructured Operations, Restructured European                   
                Operations (Details)                                             
98: R82         Severance and Retention Costs related to our        HTML     43K 
                Restructured Operations, Restructured North                      
                American TEGSEDI Operations (Details)                            
99: R83         Employment Benefits (Details)                       HTML     37K 
100: R84         Legal Proceedings (Details)                         HTML     32K  
101: R85         Fourth Quarter Financial Data (Unaudited)           HTML    156K  
                (Details)                                                        
104: XML         IDEA XML File -- Filing Summary                      XML    194K  
102: XML         XBRL Instance -- form10k_htm                         XML   4.70M  
103: EXCEL       IDEA Workbook of Financial Reports                  XLSX    175K  
13: EX-101.CAL  XBRL Calculations -- ions-20211231_cal               XML    335K 
14: EX-101.DEF  XBRL Definitions -- ions-20211231_def                XML   1.79M 
15: EX-101.LAB  XBRL Labels -- ions-20211231_lab                     XML   3.59M 
16: EX-101.PRE  XBRL Presentations -- ions-20211231_pre              XML   2.22M 
12: EX-101.SCH  XBRL Schema -- ions-20211231                         XSD    308K 
105: JSON        XBRL Instance as JSON Data -- MetaLinks              624±   948K  
106: ZIP         XBRL Zipped Folder -- 0000874015-22-000079-xbrl      Zip   1.32M  


‘EX-4.11’   —   Instrument Defining the Rights of Security Holders — exhibit4-11


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

Exhibit 4.11

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of December 31, 2021, Ionis Pharmaceuticals, Inc. (the “Company”) had one class of securities, its Common Stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
 
Description of Common Stock
 
General
 
The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), and our Amended and Restated Bylaws (the Bylaws), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.11 is a part. We encourage you to read our Certificate of Incorporation, Bylaws and the applicable provisions of the General Corporation Law of Delaware (the “DGCL”) for additional information.
 
Authorized Capital Stock
 
Our authorized capital stock consists of 300,000,000 shares of Common Stock, par value $0.001 per share, and 15,000,000 shares of Preferred Stock, par value $0.001 per share. Our board of directors has the authority, without stockholder approval, except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock.  In addition, our board of directors has the authority, without further action by our stockholders, to designate the rights, preferences, privileges and restrictions of our Preferred Stock in one or more series.
 
Voting Rights
 
Holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders, including the election of directors. Our Common Stock does not have cumulative voting rights.
 
Dividend Rights
 
Subject to the preferential rights of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may determine from time to time in its discretion.
 
Classification of the Board of Directors
 
Our Certificate of Incorporation provides for classified terms for the members of our board of directors. The board of directors is divided into three classes, and each director serves a three-year term.
 

Liquidation, Dissolution or Winding Up
 
Subject to the preferential rights of outstanding shares of Preferred Stock, if any, holders of Common Stock will share equally in all assets legally available for distribution, after payment of all liabilities, to our stockholders in the event of liquidation, dissolution or winding up of the Company.
 
Other Rights and Preferences
 
Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights.
 
Anti-Takeover Provisions
 
Delaware Anti-takeover Law
 
We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, unless:
 

the transaction is approved by the board of directors before the date the interested stockholder attained that status;

upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or

on or after the date the business combination is approved by the board and authorized at a meeting of stockholders by at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder.
 
A “business combination” is defined to include any merger or consolidation involving a corporation and the interested stockholder; any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.
 
In general, an “interested stockholder” is an entity or person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status, did own) 15% or more of a corporation’s voting stock.
 
The fair price provision and Section 203 of the DGCL could prohibit or delay mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.
 
 
Our Certificate of Incorporation includes a provision that requires at least 66-2/3% of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.
 
Provisions of our Certificate of Incorporation and Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our Certificate of Incorporation and Bylaws:
 


permit our board of directors to issue up to 15,000,000 shares of Preferred Stock, with any rights, preferences and privileges as they may designate;


provide that the authorized number of directors shall be fixed exclusively by the board of directors;


provide that the board of directors or any individual director may only be removed with cause  by the affirmative vote of the holders of at least a majority of the outstanding common stock or without cause by the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;


provide that all vacancies, including newly created directorships, may, except as otherwise required by law or subject to the rights of holders of preferred stock as designated from time to time, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, unless the board of directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders;


classifies our board of directors into three classes;


require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;


provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice;


do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of Common Stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and


provide that special meetings of our stockholders may be called only by the Chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exists any vacancies).

The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated Preferred Stock makes it possible for our board of directors to issue Preferred Stock with voting or other rights or preferences that could impede the success of any attempt to change our control.
 

These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.
 
Choice of Forum
 
Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative claim or cause of action or proceeding brought on behalf of the Company; (ii) any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the Company to the Company or the Company’s stockholders; (iii) any claim or cause of action against the Company or any current or former director or officer or other employee of the Company arising out of or pursuant to any provision of the DGCL, our Certificate of Incorporation (as may be amended from time to time) or our Bylaws (as may be amended from time to time); and (iv) any action asserting a claim against the Company or any current or former director or officer or other employee of the Company governed by the internal affairs doctrine; (v) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Bylaws or the Certificate of Incorporation of the corporation (as each may be amended from time to time, including any right, obligation, or remedy thereunder); and (vi) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision does not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of Article XV of the Bylaws.
 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed as of:2/25/22
Filed on:2/24/228-K
For Period end:12/31/215
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/21/24  Ionis Pharmaceuticals Inc.        10-K       12/31/23  103:18M
 2/22/23  Ionis Pharmaceuticals Inc.        10-K       12/31/22  110:25M


52 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/03/21  Ionis Pharmaceuticals Inc.        10-Q        9/30/21   62:11M
 8/04/21  Ionis Pharmaceuticals Inc.        10-Q        6/30/21   60:9M
 5/05/21  Ionis Pharmaceuticals Inc.        10-Q        3/31/21   57:8M
 4/23/21  Ionis Pharmaceuticals Inc.        DEF 14A     6/02/21    1:6.7M                                   Broadridge Fin’l So… Inc
 4/13/21  Ionis Pharmaceuticals Inc.        8-K:1,2,3,8 4/06/21   15:1.5M                                   Donnelley … Solutions/FA
 3/29/21  Ionis Pharmaceuticals Inc.        8-K:5,9     3/26/21   12:505K                                   Broadridge Fin’l So… Inc
 2/24/21  Ionis Pharmaceuticals Inc.        10-K       12/31/20  111:23M
12/31/20  Ionis Pharmaceuticals Inc.        S-8        12/31/20    7:376K                                   Broadridge Fin’l So… Inc
 8/31/20  Ionis Pharmaceuticals Inc.        8-K:1,8,9   8/30/20   12:712K                                   Donnelley … Solutions/FA
 8/07/20  Ionis Pharmaceuticals Inc.        S-8         8/10/20    5:159K                                   Broadridge Fin’l So… Inc
 8/05/20  Ionis Pharmaceuticals Inc.        10-Q        6/30/20   59:10M
 4/24/20  Ionis Pharmaceuticals Inc.        DEF 14A     6/04/20    1:6.1M                                   Broadridge Fin’l So… Inc
 3/02/20  Akcea Therapeutics, Inc.          10-K       12/31/19  113:18M                                    ActiveDisclosure/FA
 3/02/20  Ionis Pharmaceuticals Inc.        10-K       12/31/19  101:22M                                    Broadridge Fin’l So… Inc
12/23/19  Ionis Pharmaceuticals Inc.        8-K:1,2,3,912/19/19   11:1M                                     Broadridge Fin’l So… Inc
12/12/19  Ionis Pharmaceuticals Inc.        8-K:2,3,8,912/11/19   13:1M                                     Broadridge Fin’l So… Inc
11/06/19  Ionis Pharmaceuticals Inc.        10-Q        9/30/19   66:10M
 8/08/19  Ionis Pharmaceuticals Inc.        10-Q        6/30/19   60:10M                                    Broadridge Fin’l So… Inc
 5/09/19  Akcea Therapeutics, Inc.          10-Q        3/31/19   70:7.7M                                   ActiveDisclosure/FA
 3/26/19  Ionis Pharmaceuticals Inc.        8-K:5,9     3/22/19    4:188K                                   Broadridge Fin’l So… Inc
 3/01/19  Ionis Pharmaceuticals Inc.        10-K       12/31/18  103:21M
11/06/18  Ionis Pharmaceuticals Inc.        10-Q        9/30/18   61:10M
10/19/18  Ionis Pharmaceuticals Inc.        8-K:5,9    10/18/18    2:190K                                   Broadridge Fin’l So… Inc
 8/07/18  Ionis Pharmaceuticals Inc.        10-Q        6/30/18   62:11M
 5/07/18  Ionis Pharmaceuticals Inc.        10-Q        3/31/18   60:8.9M
 2/28/18  Ionis Pharmaceuticals Inc.        10-K       12/31/17  109:18M
 7/21/17  Ionis Pharmaceuticals Inc.        8-K:1,2,9   7/18/17    7:2.6M                                   Broadridge Fin’l So… Inc
 5/09/17  Ionis Pharmaceuticals Inc.        10-Q        3/31/17   52:7M
 3/27/17  Akcea Therapeutics, Inc.          S-1                   20:7.3M                                   Toppan Merrill-FA
 3/01/17  Ionis Pharmaceuticals Inc.        10-K       12/31/16  102:14M                                    Broadridge Fin’l So… Inc
 5/05/16  Ionis Pharmaceuticals Inc.        10-Q        3/31/16   53:5.9M
12/18/15  Ionis Pharmaceuticals Inc.        8-K:5,9    12/18/15    3:255K                                   Broadridge Fin’l So… Inc
11/09/15  Ionis Pharmaceuticals Inc.        10-Q        9/30/15   59:8.6M
 8/05/15  Ionis Pharmaceuticals Inc.        10-Q        6/30/15   58:8.6M
 5/05/15  Ionis Pharmaceuticals Inc.        10-Q        3/31/15   54:8M
 3/02/15  Ionis Pharmaceuticals Inc.        10-K       12/31/14   97:20M                                    Broadridge Fin’l So… Inc
11/21/14  Ionis Pharmaceuticals Inc.        8-K:1,2,3,911/17/14    2:951K                                   Toppan Merrill/FA
11/07/14  Ionis Pharmaceuticals Inc.        10-Q        9/30/14   59:8.3M
 8/04/14  Ionis Pharmaceuticals Inc.        10-Q        6/30/14   52:8.4M                                   Broadridge Fin’l So… Inc
 4/25/14  Ionis Pharmaceuticals Inc.        DEF 14A     6/10/14    1:1.9M                                   Broadridge Fin’l So… Inc
11/05/13  Ionis Pharmaceuticals Inc.        10-Q        9/30/13   52:11M                                    Toppan Merrill/FA
 8/06/13  Ionis Pharmaceuticals Inc.        10-Q        6/30/13   83:15M                                    Toppan Merrill/FA
 2/28/13  Ionis Pharmaceuticals Inc.        10-K       12/31/12   79:19M                                    Toppan Merrill/FA
 8/06/12  Ionis Pharmaceuticals Inc.        10-Q        6/30/12   46:8.8M                                   Toppan Merrill/FA
 5/09/12  Ionis Pharmaceuticals Inc.        10-Q        3/31/12   41:8.2M                                   Toppan Merrill/FA
 4/16/12  Ionis Pharmaceuticals Inc.        DEF 14A     6/07/12    1:1.2M                                   Toppan Merrill/FA
11/08/11  Ionis Pharmaceuticals Inc.        10-Q        9/30/11   42:8.2M                                   Toppan Merrill/FA
 8/08/11  Ionis Pharmaceuticals Inc.        S-8         8/08/11    5:287K                                   Toppan Merrill/FA
 8/08/11  Ionis Pharmaceuticals Inc.        10-Q        6/30/11   43:5.7M                                   Toppan Merrill/FA
 5/07/10  Ionis Pharmaceuticals Inc.        10-Q        3/31/10    9:3.7M                                   Toppan Merrill/FA
 5/12/08  Ionis Pharmaceuticals Inc.        10-Q        3/31/08    9:3.5M                                   Toppan Merrill/FA
12/13/00  Ionis Pharmaceuticals Inc.        8-K:5,7    12/08/00    5:207K                                   Toppan Merrill-FA2/FA
Top
Filing Submission 0000874015-22-000079   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 12, 6:32:13.4am ET